¹²⁵I-Fibrinogen Binding to Platelets in Myeloproliferative Disease

Summary

Recent reports have suggested a variation in the density and affinity of fibrinogen binding sites in platelets from patients with myeloproliferative disorders (MPD) which may reflect platelet functional abnormalities in these subjects. We have investigated the binding of ¹²⁵I-fibrinogen (¹²⁵I-Fb) to gel-filtered platelets from a large relatively homogeneous group of patients with MPD compared to normal age matched controls. Twenty-two of the patients investigated had polycythaemia vera and four essential thrombocythaemia.

The maximal density and affinity (Kd) of ¹²⁵I-Fb binding was assessed by saturation analysis in gel-filtered platelets (GFP) stimulated with either 10 εM ADP or 150 mU thrombin. In addition the functional significance of the binding sites was studied by evaluating the response of GFP from the two experimental groups by assessing the effects of increasing concentrations of added fibrinogen on the response to 10 εM ADP using standard light transmission aggregometry.

In both groups the density of fibrinogen binding sites expressed in response to thrombin stimulation was significantly higher (approximately 2-3 fold) than that found in response to ADP. However, fewer binding sites were detected in the MPD group as compared with the control group in response to both ADP and thrombin. The Kd for ¹²⁵I-Fb was similar for both agonists in normal controls and was significantly lower than that found in the MPD subjects.

Although the ¹²⁵I-Fb binding study results indicate a significant reduction in both the number and affinity of fibrinogen binding sites in patients with myeloproliferative disorders, the clinical and functional significance of these findings remain uncertain.

• References

• 1 Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1-12
• 2 Walsh PN, Murphy S, Barry WE. The role of platelets in the pathogenesis of thrombosis and haemorrhage in patients with thrombocytosis. Thromb Haemostas 1977; 38: 1085-96
• 3 Kessler CM, Klein HG, Havlik RJ. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol 1982; 50: 157-67
• 4 Marguerie GA, Ginsberg MH, Plow EF. The platelet fibrinogen receptor. In: Platelets in Biology and Pathology III.. MacIntyre DE, Gordon AL. (eds) Elsevier Science Publishers, Amsterdam: 1987. pp 95-125
• 5 Landolfi R, De Cristo Faro R, Catagnola M, De Candia E, D'Onofrio G, Leone G, Bizzi B. Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders. Blood 1988; 71: 978-82
• 6 Mazzucato M, De Marco L, De Angelis V, De Roia D, Bizzaro N, Casonato A. Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoprotein Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol 1989; 73: 369-74
• 7 Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem 1980; 255: 154-61
• 8 Kazal LA, Amsel S, Miller OP, Tocantins LM. The preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc Soc Exp Biol Med 1963; 113: 989-94
• 9 Hawiger J, Parkinson S, Timmons S. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets. Nature 1980; 283: 195-7
• 10 Peerschke EIB. Effect of epinephrine on fibrinogen receptor exposure by aspirin-treated platelets and platelets from concentrates in response to ADP and thrombin. Am J Hematol 1984; 16: 335-45
• 11 Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660-72
• 12 Plow EF, Marguerie GA. Participation of ADP in the binding of fibrinogen to thrombin-stimulated platelets. Blood 1980; 56: 553-5
• 13 Clezardin P, McGregor JL, Dechavanne M, Clemetson KJ. Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis. Br J Haematol 1985; 60: 331-44